Tenax Therapeutics Q4 net loss widens on higher R&D expenses

Tenax Therapeutics

10/03/2026 11:11

Overview

U.S. pharmaceutical firm's Q4 net loss widened to $15.5 mln

Company achieved randomization target in Phase 3 LEVEL study, topline data expected Q3 2026

Company initiated global Phase 3 LEVEL-2 trial and opened long-term OLE study

Outlook

Tenax expects to complete enrollment for LEVEL-2 study by end of 2027

Company anticipates sharing topline data from LEVEL study in Q3 2026

Tenax expects cash reserves to fund operations through 2027

Result Drivers

R&D EXPENSES - Increased R&D expenses attributed to ongoing LEVEL trial and initiation of LEVEL-2 study

RANDOMIZATION TARGET - Achieved randomization target of 230 patients in LEVEL study, topline data expected Q3 2026

GLOBAL TRIAL EXPANSION - Focus on activating clinical sites globally for LEVEL-2 study, aiming for enrollment completion by end of 2027

Company press release: ID:nGNX4zGRp1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$15.54 mln
Q4 Operating Expenses
$16.45 mln
Q4 Operating Income
-$16.45 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Tenax Therapeutics Inc is $25.50, about 131.4% above its March 9 closing price of $11.02

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)